Group A streptococcal disease in the 1990s: New clues to pathogenesis

International Journal of Infectious Diseases

Volumn 1, Issue 2, 1996, Pages 107-114

  Wessels, Michael R ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c Charming Laboratory   (United States)

Author keywords

Capsular polysaccharide; Group A streptococcus; Hyaluronic acid; M protein; Necrotizing fasciitis; Pyrogenic exotoxin; Rheumatic fever; Streptococcus pyogenes; Toxic shock syndrome

Indexed keywords

EID: 0000669401     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1201-9712(96)90064-8     Document Type: Review

References (61)

1. Pini P. Superbug stars in media-made epidemic. Lancet 1994; 343:1376-1377.
2. Descamps V, Aitken J, Lee MG. Hippocrates on necrotising fasciitis. Lancet 1994; 344:556.
3. Hippocrates. Epidemics. Vol I London: Heinemann, for Harvard University Press, 1957:24-43.
4. Katz AR, Morens DM. Severe streptococcal infection in historical perspective. Clin Infect Dis 1992; 14:298-307.
5. Massell B, Chute C, Walker A, Kurland G. Penicillin and the marked decrease in morbidity and mortality from rheumatic fever in the United States. N Engl J Med 1988; 318:280-286.
6. Veasy LG, Wiedmeier SE, Orsmond GS, et al. Resurgence of acute rheumatic fever in the intermountain area of the United States. N Engl J Med 1987; 316:1298-1315.
7. Hosier DM, Craenen M, Teske DW, Wheller JJ. Resurgence of acute rheumatic fever. Am J Dis Child 1987; 141:730-733.
8. Marcon MJ, Hribar MM, Hosier DM, et al. Occurrence of mucoid M-18 Streptococcus pyogenes in a central Ohio pediatric population. J Clin Microbiol 1988; 26:1539-1542.
9. Westlake R, Graham T, Edwards K. An outbreak of acute rheumatic fever in Tennessee. Pediatr Infect Dis J 1990; 9(1):97-100.
10. Cone LA, Woodard DR, Schlievert PM, Tomory GS. Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N Engl J Med 1987; 317:146-149.
11. Stevens DL, Tanner MH, Winship J, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 1989; 321:1-8
12. Hoge CW, Schwartz B, Talkington DF, Breiman RF, MacNeill EM, Englender SJ. The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome. JAMA 1993, 269:384-389.
13. Carapetis J, Robins-Browne R, Martin D, Shelby-James T, Hogg G. Increasing severity of invasive group A streptococcal disease in Australia: clinical and molecular epidemiological features and identification of a new virulent M-nontypeable clone. Clin Infect Dis 1995; 21:1220-1227.
14. Wheeler MC, Roe MH, Kaplan EL, Schlievert PM, Todd JK. Outbreak of group A streptococcus septicemia in children. JAMA 1991; 266:533-537.
15. Brogan TV, Nizet V, Waldhausen JHT, Rubens CE, Clarke WR. Group A streptococcal necrotizing fasciitis complicating primary varicella: a series of fourteen patients. Pediatr Infect Dis J 1995; 14.588-594.
16. Doctor A, Harper MB, Fleisher GR. Group A β-hemolytic streptococcal bacteremia: historical overview, changing inci- dence, and recent association with varicella. Pediatrics 1995; 96:428-433.
17. Vugia DJ, Peterson CL, Meyers HB, et al. Invasive group A steptococcal infections in children with varicella in southern California. Pediatr Infect Dis J 1996; 15:145-150.
18. Lancefield RC. Current knowledge of the type specific M antigens of group A streptococci. J Immunol 1962; 89:307-313.
19. Beachey EH, Stollerman GH, Chiang EY, Chiang TM, Seyer JM, Kang AH. Purification and properties of M protein extracted from group A streptococci with pepsin: covalent structure of the amino terminal region of type 24 M antigen. J Exp Med 1977; 145:1469-1483.
20. Manjula BN, Fischetti VA. Studies on group A streptococcal M-proteins. purification of type 5 M-protein and comparison of its amino terminal sequence with two immunologically unrelated M-protein molecules. J Immunol 1980; 124:261-267.
21. Fischetti VA. Streptococcal M protein: molecular design and biological behavior. Clin Microbiol Rev 1989; 2:285-314.
22. Horstmann RD, Sievertsen HJ, Knobloch J, Fischetti VA. Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H. Proc Natl Acad Sci U S A 1988; 85:1657-1661.
23. Perez-Casal J, Okada N, Caparon MG, Scott JR. Role of the conserved C-repeat region of the M protein of Streptococcus pyogenes. Mol Microbiol 1995; 15:907-916.
24. Whitnack E, Beachey EH. Antiopsonic activity of fibrinogen bound to M protein on the surface of group A streptococci. J Clin Invest 1982; 69:1042-1045.
25. Jacks-Weis J, Kim Y, Cleary PP. Restricted deposition of C3 on M+ group A streptococci: correlation with resistance to phagocytosis. J Immunol 1982; 128(4):1897-1902.
26. Dale JB, Washburn RG, Marques MB, Wessels MR. Hyaluronate capsule and surface M protein in resistance to opsonization of group A streptococci. Infect Immun 1996; 64:1495-1501.
27. O'Toole P, Stenberg L, Rissler M, Lindahl G. Two major classes in the M protein family in group A streptococci. Proc Natl Acad Sci U S A 1992; 89:8661-8665.
28. Podbielski A. Three different types of organization of the vir regulon in group A streptococci. Mol Gen Genet 1993; 237:287-300.
29. Hollingshead SK, Readdy TL, Yung DL, Bessen DE. Structural heterogeneity of the emm gene cluster in group A streptococci. Mol Microbiol 1993; 8:707-717.
30. Wexler DE, Chenoweth ED, Cleary PP. Mechanism of action of the group A streptococcal C5a inactivator. Proc Natl Acad Sci USA 1985; 82:8144-8148.
31. Ji Y, McLandsborough L, Kondagunta A, Cleary PP. C5a peptidase alters clearance and trafficking of group A streptococci by infected mice. Infect Immun 1996; 64:503-510.
32. Simpson WJ, LaPenta D, Chen C, Cleary PP Coregulation of type 12 M protein and streptococcal C5a peptidase genes in group A streptococci: evidence for a virulence regulon controlled by the virR locus. J Bacteriol 1990; 172:696-700.
33. Perez-Casal J, Caparon MG, Scott JR. Mry, a trans-acting positive regulator of the M protein gene of Streptococcus pyogenes with similarity to the receptor proteins of two-component regulatory systems. J Bacteriol 1991; 173:2617-2624.
34. Okada N, Geist RT, Caparon MG. Positive transcriptional control of mry regulates virulence in the group A streptococcus. Mol Microbiol 1993; 7:893-903.
35. McIver KS, Heath AS. Green BD, Scott JR. Specific binding of the activator Mga to promoter sequences of the emm and scpA genes in the group A streptococcus. J Bacteriol 1995; 177:6619-6624.
36. Bessen DE, Fischetti VA. Nucleotide sequences of two adjacent M or M-like protein genes of group A streptococci: different RNA transcript levels and identification of a unique immunoglobulin A-binding protein. Infect Immun 1992; 60:124-135.
37. Boyle MDP, Hawlitzky J, Raeder R, Podbielski A. Analysis of genes encoding two unique type IIa immunoglobulin G-binding proteins expressed by a single group A streptococcal isolate. Infect Immun 1994; 62:1336-1347.
38. Akesson P, Schmidt K-H, Cooney J, Bjorck L. M1 protein and protein H: IgGFc- and albumin-binding streptococcal surface proteins encoded by adjacent genes. Biochem J 1994; 300:877-886.
39. Them A, Stenberg L, Dahlback B, Lindahl G. Ig-binding surface proteins of Streptococcus pyogenes also bind human C4b-binding protein (C4BP), a regulatory component of the complement system. J Immunol 1995; 154:375-386.
40. Podbielski A, Schnitzler N, Beyhs P, Boyle MDP. M-related protein (Mrp) contributes to group A streptococcal resistance to phagocytosis by human granulocytes. Mol Microbiol 1996; 19:429-441.
41. Johnson DR, Stevens DL, Kaplan EL. Epidemiologic analysis of group A streptococcal serotypes associated with severe systemic infections, rheumatic fever, or uncomplicated pharyngitis. J Infect Dis 1992; 166:374-382.
42. Holm SE, Norrby A, Bergholm A-M, Norgren M. Aspects of pathogenesis of serious streptococcal infection in Sweden, 1988-89. J Infect Dis 1992, 166:31-37.
43. Colman G, Tanna A, Efstratiou A, Gaworzewska ET. The serotypes of Streptococcus pyogenes present in Britain during 1980-1990 and their association with disease. J Med Microbiol 1993; 39:165-178.
44. Schwartz B, Facklam RR, Breiman RE Changing epidemiology of group A streptococcal infection in the USA. Lancet 1990; 336:1167-1171.
45. Cleary PP, Kaplan EL, Handley JP et al. Clonal basis for resurgence of serious Streptococcus pyogenes disease in the 1980s. Lancet 1992; 339:518-521.
46. Musser JM, Hauser AR, Kim MH, Schlievert PM, Nelson K, Selander RK. Streptococcus pyogenes causing toxic shock-like syndrome and other invasive diseases: clonal diversity and pyrogenic exotoxin expression. Proc Natl Acad Sci USA 1991; 88:2668-2672.
47. Musser JM, Kapur V, Szeto JXP, Swanson D, Martin D. Genetic diversity and relationships among Streptococcus pyogenes strains expressing serotype M1 protein: recent intercontinental spread of a subclone causing episodes of invasive disease. Infect Immun 1995; 63:994-1003.
48. Weeks CR, Ferretti JJ. The gene for type A streptococcal exotoxin (erythrogenic toxin) is located in bacteriophage T12. Infect Immun 1984; 46:531-536.
49. Goshorn SC, Schlievert PM. Nucleotide sequence of streptococcal pyrogenic exotoxin C. Infect Immun 1988; 56:2518-2520.
50. Kapur V, Majesky MW, Li L-L, Black RA, Musser JM. Cleavage of interleukin 1β precursor to produce active IL-1β by a conserved extracellular cysteine protease from Streptococcus pyogenes. Proc Natl Acad Sci USA 1993; 90:7676-7680.
51. Abe J, Forrester J, Nakahara T, Lafferty JA. Selective stimulation of human T cells with streptococcal erythrogenic toxins A and B. J Immunol 1991; 146:3747-3750.
52. Braun MA, Gerlach D, Hartwig UF, et al. Stimulation of human T cells by streptococcal "'superantigen" erythrogenic toxins (scarlet fever toxins). J Immunol 1993; 150:2457-2466.
53. Eagle H. Experimental approach to the problem of treatment failure with penicillin. I. Group A streptococcal infection in mice. Am J Med 1952; 13:389-399.
54. Stevens DL, Gibbons AE, Bergstrom R, Winn V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 1988; 158:23-28.
55. Norrby-Teglund A, Kaul R, Low DE, et al. Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. J Immunol 1996; 156:3057-3064.
56. Kaul R, McGeer A, Norrby-Teglund A, Kotb M, Low DE. Intravenous immunoglobulin (TVIG) therapy in streptococcal toxic shock syndrome (STSS): results of a matched case-control study [Abstract LM68]. In: Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology. 1995.
57. Sandson J, Hamerman D, Janic R, Rojkind M. Immunologic and chemical similarities between the streptococcus and human connective tissue. Trans Assoc Am Physicians 1968; 81:249-257.
58. Wilson AT. The relative importance of the capsule and the M antigen in determining colony form of group A streptococci. J Exp Med 1959; 109:257-270.
59. Wessels MR, Moses AE, Goldberg JB, DiCesare TJ. Hyaluronic acid capsule is a virulence factor for mucoid group A streptococci. Proc Natl Acad Sci USA 1991; 88:8317-8321.
60. Wessels MR, Goldberg JB, Moses AE, DiCesare TJ. Effects on virulence of mutations in a locus essential for hyaluronic acid capsule expression in group A streptococci. Infect Immun 1994; 62:433-441.
61. Wessels MR, Bronze MS. Critical role of the group A streptococcal capsule in pharyngeal colonization and infection in mice. Proc Natl Acad Sci U S A 1994; 91:12238-12242.